transparent gif
ArthritisSupport.com Home  
Staph Infection Process Leading to B Cell Suicide Described for First Time
Arthritis Home Page Arthritis Library Arthritis Treatment and Research Email bulletins Arthritis Products Arthritis Community Area Arthritis About Us transparent gif transparent gif
transparent gif
background The Latest News Articles background The Latest Abstracts background The Latest Drug News background
Search Our Site
 
 Arthritis Info.
Arthritis Resources

Your Support Funds Research & Advocacy

Staph Infection Process Leading to B Cell Suicide Described for First Time


arthritissupport.com

05-07-2003

Advertisement
Researchers at the University of California, San Diego—supported by the Alliance for Lupus Research and the National Institutes of Health—have for the first time described a method that Staphylococcus aureus (staph) infection uses to inactivate the body’s immune system. A protein produced by the staph bacteria causes previously healthy B cells—a specialized cell of the immune system—to commit suicide, a process called apoptosis. The research will be published in the May 5 issue of the Journal of Experimental Medicine.

In the new study, the researchers found that SpA, a staph protein, functions as a B cell toxin in mice. The protein attaches to a receptor on B cells, eventually causing the B cells to turn on themselves in a suicide process.

Researchers believe that B cells play a major role in tissue damage that occurs in lupus. “By the targeted elimination of disease-causing B cells, properly dosed injections of SpA may have the potential to control the over-activity of the immune system that causes damage in autoimmune diseases like lupus and in certain cancers,” said Gregg Silverman, M.D., UCSD professor of medicine and senior author of the paper.

“The significance of Dr. Silverman’s research is that the discovery that injections of SpA limit the activity of B cells in animals allows us to proceed to the next step, to test the protein’s usefulness in people,” said John H. Klippel, MD, scientific director of the Alliance for Lupus Research, which funded this study. “If results hold true for people, SpA may eventually prove to be an effective treatment for lupus.”

In addition to Silverman, the study was conducted by the paper’s co-author Carl S. Goodyear, Ph.D., a UCSD postdoctoral researcher.

The study was funded by the National Institutes of Health and the Alliance for Lupus Research.

  Newsletter SignUp Discuss (0 comments) Email Article Print Page
Related Articles:
Scientists Identify Two Key Risk Factors for Hip Replacement in Women
Rating of 3.3
CDC: Older Adults With Arthritis To Double By 2030
Rating of 3.1
Pathogenic Yeasts and Fungi: A Growing Health Concern (Especially for Immune Compromised Individuals)
Rating of 3
Camera Pill Reveals Damage From Anti-inflammatory Drugs
Rating of 3.2
Researchers Discover Mechanism That May Trigger Autoimmune Disease
Rating of 3.1

Every purchase funds research, donations and the community resources provided within our website.

Organic & pure - 100% acacia
RenewLife Clear Fiber

Buffered for easy absorption
Pro-C Complex™ 500mg

Our new proprietary energy NADH
Energy NADH™ 10 mg

Getting your daily supplements has never been easier!
Daily Health ProPack™

At ProHealth we believe in "commerce with compassion."

Weekly Special





[ Be the first to comment on this article ]
DISCUSS THIS ARTICLE  (0 existing comments)
Post a Comment
transparent gif
transparent gif transparent gif transparent gif

Home | Library | Email Bulletins | Store | Community | Affiliates


ProHealth's ArthritisSupport.com-
Email US or Call US at 1-800-366-6056
Monday-Friday, 7 a.m.-5 p.m. PST
International Callers can reach us at 001.805.564.3064
Copyright © 2008 ProHealth, Inc.
About us, Affiliates, Careers, Contact us, Privacy, 30-day Money Back Guarantee